Full Year 2025 Grifols SA Earnings Call Transcript
Key Points
- Grifols SA (GRFS) reported a solid 7% increase in revenue for 2025, reaching EUR7,524 million, driven by strong performance in its immunoglobulin (Ig) franchise.
- The company achieved a significant increase in free cash flow, generating EUR468 million pre-M&A and pre-dividends, reflecting improved capital discipline.
- Adjusted EBITDA grew by 5.6% year-over-year, with a like-for-like increase of close to 12% at constant currency, aligning with the company's guidance.
- Grifols SA (GRFS) successfully launched new products, including a fibrinogen concentrate in Europe and plans to launch in the US following FDA approval.
- The company's strategic partnerships in Egypt and Canada are expected to redefine the plasma industry, with significant milestones achieved, such as EMA approval for Egyptian source plasma.
- Albumin sales in China declined due to government cost controls, impacting overall margins and highlighting challenges in the Chinese market.
- The company's gross margin was weaker compared to 2024, affected by the impact of the Inflation Reduction Act (IRA) and market dynamics in China.
- Despite revenue growth, Grifols SA (GRFS) faces challenges in balancing growth with profitability, particularly in optimizing plasma economics and production costs.
- The company is not providing specific revenue growth guidance for 2026, indicating a focus on margin-accretive growth rather than top-line expansion.
- Grifols SA (GRFS) continues to face geopolitical and macroeconomic uncertainties, which could impact its operations and financial performance.
Hello, everyone, and thank you for joining us today for Grifol's fourth-quarter and full-year 2025 earnings call. My name is Daniel Segarra, and I serve as the Head of Investor Relations and Sustainability.
Today, I'm joined by Grifol's Chief Executive Officer, Nacho Abia; President of Biopharma, Roland Wandeler, and Chief Financial Officer, Rahul Srinivasan. It is our usual practice. Today's call will last about an hour, including the Q&A session. Please note that this call is being recorded.
You can find additional materials, including today's presentation in the Investor Relations section of the Grifols website at grifols.com. A transcript and replay of the webcast will also be available on the Investor Relations website within 24 hours.
Turning to slide 2. I would like to remind everyone that forward-looking statements may be made during this call. This may include, among other things, comments regarding the company's future operating and financial performance, statements about our future
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
